 |
12 Diseases |  |
138 Trials |
|
138 Trials |  |
3994 News |  |
| «12...28293031323334353637383940» |
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk, semaglutide SC once-daily (NN9536) / Novo Nordisk
Clinical, Journal: Semaglutide: First Global Approval. (Pubmed Central) - Apr 5, 2019
Clinical development for obesity, non-alcoholic steatohepatitis and non-alcoholic fatty liver disease is underway worldwide. This article summarizes the milestones in the development of semaglutide leading to this first approval for type 2 diabetes.
- | Victoza (liraglutide) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk, semaglutide SC once-daily (NN9536) / Novo Nordisk
Clinical, Review, Journal: The efficacy and safety of exenatide once weekly in patients with type 2 diabetes. (Pubmed Central) - Apr 5, 2019
Currently, the overall risk-benefit profiles for the range of GLP-1RAs point to liraglutide and semaglutide as first-choice for the management of T2D, which has been confirmed by a recently published consensus report on the treatment of T2D from the American Diabetes Association and the European Association for the Study of Diabetes. The pricing of exenatide QW will most likely be a key determinant for its place in the future management of T2D.
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Januvia (sitagliptin) / Merck (MSD), semaglutide SC once-daily (NN9536) / Novo Nordisk
Clinical, Journal: Reductions in insulin resistance are mediated primarily via weight loss in subjects with type 2 diabetes on semaglutide. (Pubmed Central) - Apr 4, 2019
Semaglutide consistently reduced BW and IR in subjects with T2D in SUSTAIN 1-3. In this analysis, IR improvement was positively associated with, and primarily mediated by, the effect of semaglutide on BW.
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
New P2/3 trial: Triple Therapy in T1DM (clinicaltrials.gov) - Apr 2, 2019
P2/3, N=114, Not yet recruiting, Sponsor: State University of New York at Buffalo
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Trulicity (dulaglutide) / Eli Lilly
Journal, HEOR: Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada. (Pubmed Central) - Mar 31, 2019
In this analysis, IR improvement was positively associated with, and primarily mediated by, the effect of semaglutide on BW. From a Canadian societal perspective, semaglutide may be a cost-effective treatment option versus dulaglutide in patients with T2D who are inadequately controlled on metformin monotherapy.
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New P2 trial: Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES) (clinicaltrials.gov) - Mar 21, 2019
P2, N=84, Recruiting, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- |||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New trial, Real-world evidence, Real-world: A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in United Kingdom, as Part of Local Clinical Practice (SURE UK) (clinicaltrials.gov) - Mar 15, 2019
P, N=217, Not yet recruiting, Sponsor: Novo Nordisk A/S
- ||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment closed: Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity (clinicaltrials.gov) - Mar 5, 2019
P3, N=300, Active, not recruiting, Sponsor: Novo Nordisk A/S
From a Canadian societal perspective, semaglutide may be a cost-effective treatment option versus dulaglutide in patients with T2D who are inadequately controlled on metformin monotherapy. Recruiting --> Active, not recruiting
- ||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment open: A Research Study to Look at How Semaglutide Affects Gastric Emptying in People With Obesity (clinicaltrials.gov) - Feb 28, 2019
P1, N=72, Recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New P1 trial: A Research Study to Look at How Semaglutide Affects Gastric Emptying in People With Obesity (clinicaltrials.gov) - Feb 15, 2019
P1, N=72, Not yet recruiting, Sponsor: Novo Nordisk A/S
- | Byetta (exenatide) / AstraZeneca, Januvia (sitagliptin) / Merck (MSD), semaglutide SC once-daily (NN9536) / Novo Nordisk
Retrospective data, Journal: Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: pooled analysis of the SUSTAIN 1-5 trials. (Pubmed Central) - Feb 8, 2019
Patients were randomized to once-weekly subcutaneous semaglutide (0.5 or 1.0 mg) vs placebo, sitagliptin, exenatide or insulin...No increased risk of severe or blood glucose-confirmed hypoglycaemia was seen with semaglutide vs comparators between both groups. Semaglutide had a comparable efficacy and safety profile in non-elderly and elderly patients across the SUSTAIN 1-5 trials, making it an effective treatment option for elderly patients with T2D.
- |||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment open: STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity (clinicaltrials.gov) - Jan 24, 2019
P3, N=400, Recruiting, Sponsor: Novo Nordisk A/S
Semaglutide had a comparable efficacy and safety profile in non-elderly and elderly patients across the SUSTAIN 1-5 trials, making it an effective treatment option for elderly patients with T2D. Not yet recruiting --> Recruiting
- ||| LAI287/semaglutide (NN1535) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Awiqli (insulin icodec) / Novo Nordisk
Enrollment open: A Research Study to Look at How Insulin 287 and Semaglutide Work in the Body of People With Type 2 Diabetes When Taken Alone or Together (clinicaltrials.gov) - Jan 24, 2019
P1, N=60, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| Trulicity (dulaglutide) / Eli Lilly
Enrollment open: A Study Comparing the Dulaglutide Pen and the Semaglutide Pen (clinicaltrials.gov) - Jan 23, 2019
P4, N=296, Recruiting, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New P3 trial: STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity (clinicaltrials.gov) - Jan 22, 2019
P3, N=400, Not yet recruiting, Sponsor: Novo Nordisk A/S
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New P3 trial: FOCUS: A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes (clinicaltrials.gov) - Jan 21, 2019
P3, N=1500, Not yet recruiting, Sponsor: Novo Nordisk A/S
- ||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment closed: STEP 2: Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity (clinicaltrials.gov) - Jan 7, 2019
P3, N=1200, Active, not recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| LAI287/semaglutide (NN1535) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Awiqli (insulin icodec) / Novo Nordisk
New P1 trial: A Research Study to Look at How Insulin 287 and Semaglutide Work in the Body of People With Type 2 Diabetes When Taken Alone or Together (clinicaltrials.gov) - Dec 27, 2018
P1, N=60, Not yet recruiting, Sponsor: Novo Nordisk A/S
- ||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment closed: STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity (clinicaltrials.gov) - Dec 24, 2018
P3, N=1950, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion: SUSTAIN 8: Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Dec 6, 2018
P3, N=788, Completed, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment closed: Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program (clinicaltrials.gov) - Dec 3, 2018
P3, N=600, Active, not recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment closed: STEP 4: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity (clinicaltrials.gov) - Nov 27, 2018
P3, N=1060, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial primary completion date: Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT) (clinicaltrials.gov) - Nov 23, 2018
P3, N=858, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2018 --> Mar 2019
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment change: Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity (clinicaltrials.gov) - Nov 1, 2018
P3, N=300, Recruiting, Sponsor: Novo Nordisk A/S
Trial primary completion date: Sep 2018 --> Mar 2019 N=88 --> 300
- | Trulicity (dulaglutide) / Eli Lilly
New P4 trial: A Study Comparing the Dulaglutide Pen and the Semaglutide Pen (clinicaltrials.gov) - Oct 29, 2018
P4, N=296, Not yet recruiting, Sponsor: Eli Lilly and Company
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial primary completion date: STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity (clinicaltrials.gov) - Oct 25, 2018
P3, N=1950, Recruiting, Sponsor: Novo Nordisk A/S
N=88 --> 300 Trial primary completion date: Sep 2019 --> Mar 2020
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment open: Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity (clinicaltrials.gov) - Oct 9, 2018
P3, N=88, Recruiting, Sponsor: Novo Nordisk A/S
Trial primary completion date: Sep 2019 --> Mar 2020 Not yet recruiting --> Recruiting
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment open: SUSTAIN 11: A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes (clinicaltrials.gov) - Oct 9, 2018
P3, N=2043, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New P3 trial: Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity (clinicaltrials.gov) - Oct 3, 2018
P3, N=88, Not yet recruiting, Sponsor: Novo Nordisk A/S
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New P3 trial: SUSTAIN 11: A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes (clinicaltrials.gov) - Sep 27, 2018
P3, N=2043, Not yet recruiting, Sponsor: Novo Nordisk A/S
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment open, Real-world evidence, Real-world: A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice (SURE SWITZERLAND) (clinicaltrials.gov) - Sep 26, 2018
P=N/A, N=217, Enrolling by invitation, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Not yet recruiting --> Enrolling by invitation
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment open, Real-world evidence, Real-world: A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Denmark and Sweden, as Part of Local Clinical Practice (SURE DENMARK/SWEDEN) (clinicaltrials.gov) - Sep 13, 2018
P=N/A, N=217, Enrolling by invitation, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Enrolling by invitation Not yet recruiting --> Enrolling by invitation
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment closed: Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT) (clinicaltrials.gov) - Aug 31, 2018
P3, N=858, Active, not recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Enrolling by invitation Recruiting --> Active, not recruiting
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment open, Trial primary completion date, HEOR, Real-world evidence, Real-world: Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial (clinicaltrials.gov) - Aug 27, 2018
P4, N=2250, Recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2019 --> Nov 2020
- | Victoza (liraglutide) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion, Trial initiation date: SUSTAIN 10: Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes (clinicaltrials.gov) - Aug 17, 2018
P3, N=577, Completed, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2019 --> Nov 2020 Active, not recruiting --> Completed | Initiation date: Jan 2017 --> Jun 2017
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion: SUSTAIN 9: Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Aug 9, 2018
P3, N=302, Completed, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed | Initiation date: Jan 2017 --> Jun 2017 Active, not recruiting --> Completed
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion: A Trial to Assess the Pharmacokinetics, Safety and Tolerability of Semaglutide in Healthy Chinese Subjects (clinicaltrials.gov) - Aug 9, 2018
P1, N=36, Completed, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk, cagrilintide (AM833) / Novo Nordisk
Enrollment open, Combination therapy: A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese (clinicaltrials.gov) - Aug 8, 2018
P1, N=80, Recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment open, Real-world evidence, Real-world: SURE CANADA: A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice (clinicaltrials.gov) - Aug 7, 2018
P=N/A, N=217, Enrolling by invitation, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Not yet recruiting --> Enrolling by invitation
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment open: Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program (clinicaltrials.gov) - Aug 6, 2018
P3, N=600, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Enrolling by invitation Not yet recruiting --> Recruiting
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New P3 trial: Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program (clinicaltrials.gov) - Aug 1, 2018
P3, N=600, Not yet recruiting, Sponsor: Novo Nordisk A/S
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk, cagrilintide (AM833) / Novo Nordisk
New P1 trial, Combination therapy: A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese (clinicaltrials.gov) - Jul 26, 2018
P1, N=80, Not yet recruiting, Sponsor: Novo Nordisk A/S
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New P4 trial, HEOR, Real-world evidence, Real-world: Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial (clinicaltrials.gov) - Jul 22, 2018
P4, N=2250, Not yet recruiting, Sponsor: Novo Nordisk A/S
- | Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion, Combination therapy: PIONEER 10: Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes (clinicaltrials.gov) - Jul 17, 2018
P3, N=458, Completed, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk, PYY 1562 / Novo Nordisk
New P1 trial: A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese (clinicaltrials.gov) - Jul 2, 2018
P1, N=48, Recruiting, Sponsor: Novo Nordisk A/S
- |||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment open: STEP 2: Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity (clinicaltrials.gov) - Jun 19, 2018
P3, N=1200, Recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New P3 trial: STEP 2: Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity (clinicaltrials.gov) - Jun 11, 2018
P3, N=1200, Not yet recruiting, Sponsor: Novo Nordisk A/S
- |||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment open: STEP 4: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity (clinicaltrials.gov) - Jun 11, 2018
P3, N=1060, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment open: STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity (clinicaltrials.gov) - Jun 8, 2018
P3, N=1950, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| Victoza (liraglutide) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial initiation date: SUSTAIN 10: Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes (clinicaltrials.gov) - Jun 8, 2018
P3, N=576, Active, not recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Initiation date: Jun 2017 --> Jan 2017